S.Korea's Celltrion: Surges as co completes patient recruitment for COVID-19 drug trial

Celltrion Pharm

25/11/2020 01:22

** South Korean drugmaker's shares  068270.KS  jump as much
as 7% to 322,500 won ($291.26), highest since Aug.10
    ** Celltrion says has completed global patient recruitment
for Phase-2 trial of its COVID-19 antibody candidate, CT-P59
    ** Says recruited 327 patients, up from original plan of 300
    ** Affiliates Celltrion Pharm  068760.KQ  and Celltrion
Healthcare  091990.KQ  surge 23.2% and 7.1%, respectively
    ** Celltrion CEO on Tuesday said co would provide treatment
at production cost, adding it has already secured stocks for
domestic usage - local media
    ** Co on Nov. 6 said CT-P59 in a small-size early-stage
trial showed at least a 44% improvement in recovery time
 urn:newsml:reuters.com:*:nL1N2HS03P 
    ** Broader KOSPI  .KS11  and junior KOSDAQ  .KQ11  both up
0.7% as of 0120 GMT


($1 = 1,107.2700 won)

 (Reporting by Joori Roh)
 ((joori.roh@thomsonreuters.com; +82 2 6936 1493;))